盐酸曲美他嗪 T0988

Product Introduction
Bioactivity


英文名: Trimetazidine dihydrochloride

描述: Trimetazidine dihydrochloride (Vastarel F) 是细胞保护性抗缺血剂，也用作缺血性心脏病或心绞痛的血管扩张剂，具有抗氧化，抗炎，抗伤害和胃保护作用。它可通过抑制脂肪酸代谢提高心肌葡萄糖利用率。

细胞实验: The H9C2 cells are randomly assigned into three groups: Sham group, in which the cells are treated with 0μM TMZ for 48 h and then cultured under normal oxygenation conditions (5% CO2, and 95% air); H/R group, in which cells are treated with 0 μM TMZ for 48 h and then cultured under H/R conditions; and H/R+TMZ group, in which cells are treated with 10 μM TMZ for 48 h and then subjected to H/R treatment. (Only for Reference)

体外活性: Trimetazidine通过上调miR-21表达靶向PTEN，增强PI3K通路的活性，抵抗缺氧/再灌注[3]的凋亡作用。

体内活性: TMZ给药可减小WT C57BL/6J心脏的心肌梗塞面积。AMPK与ERK信号传导途径共同介导了TMZ对缺血性损伤的心脏保护作用。Trimetazidine转变新陈代谢从脂肪酸氧化向葡萄糖氧化，并在缺氧条件下改善心肌细胞的收缩功能[2]。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 70 mg/mL (206.33 mM)


关键字: inhibit | Trimetazidine dihydrochloride | Trimetazidine | Autophagy | Inhibitor | Trimetazidine Dihydrochloride

相关产品: SP-8356 | Ivacaftor | Naproxen | KN-62 | Tacrolimus monohydrate | palovarotene | NL-1 | RSVA405 | Succinylsulfathiazole | Megestrol acetate

相关库: Drug Repurposing Compound Library | Approved Drug Library | Oxidation-Reduction Compound Library | Anti-Cancer Drug Library | Bioactive Compounds Library Max | Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Approved Drug Library | EMA Approved Drug Library | Autophagy Compound Library

盐酸曲美他嗪 T0988信息由TargetMol中国为您提供，如您想了解更多关于盐酸曲美他嗪 T0988报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途